顶峰治疗
SMMT
14.63
-0.74
-4.81%
顶峰治疗
US · SMMT
#1207 按市值排名
上市于 2015
14.63
-0.74
-4.81%
实时 - 追踪5344个代码 - 心跳于205秒前
· 2026-10-16 19:58
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例下降了0.3个百分点。
机构持股
- 机构持股比例
- 21.29% -0.29pp
- 机构数量
- 287 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Individual/Insider76.69%
Mutual Fund8.67%
Hedge Fund7.21%
Public Company4.98%
Private Company0.18%
Sovereign Wealth Fund0.18%
Other2.02%
主要股东 截至 2026-06-12
Robert Duggan
71.76% · 573.88M 股
Mahkam Zanganeh
4.52% · 36.13M 股
Baker Bros. Advisors LP
4.10% · 32.79M 股
Akeso, Inc.
4.01% · 32.06M 股
FMR
1.26% · 10.04M 股
State Street Global Advisors
1.19% · 9.54M 股
BlackRock
1.19% · 9.53M 股
Vanguard Capital Management, LLC
0.84% · 6.70M 股
UBS Asset Management
0.67% · 5.32M 股
Vanguard Portfolio Management, LLC
0.63% · 5.04M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 48次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Robert Duggan | Co-CEO & Executive Chairman | 71.76% |
| Mahkam Zanganeh | Co-Chief Executive Officer | 4.52% |
| Manmeet Soni | Chief Operating Officer | 0.39% |
| Bhaskar Anand | Chief Accounting Officer & Head of Finance | 0.02% |
| Jeffrey Huber | Director | 0.01% |
| Kenneth Clark | Independent Non-Executive Director | -- |
| Robert F. Booth | Independent Director | -- |
| Mostafa Ronaghi | Director | -- |
| Alessandra Cesano | Independent Non-Executive Director | -- |
| Akeso, Inc. | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-11 | Robert Duggan | Co-CEO & Executive Chairman | Open Market Acquisition | +3,810,000 | $13.12 |
| 2026-06-03 | Mahkam Zanganeh | Co-Chief Executive Officer | Open Market Acquisition | +100,000 | $14.60 |
| 2026-06-03 | Manmeet Soni | Chief Operating Officer | Open Market Acquisition | +50,000 | $14.43–14.46 |
| 2026-01-07 | Bhaskar Anand | Chief Accounting Officer & Head of Finance | Other Derivative Acquisition | +30,000 | $18.83 |
| 2026-01-01 | Kenneth Clark | Independent Non-Executive Director | Other Derivative Acquisition | +52,796 | $17.52 |
| 2026-01-01 | Robert F. Booth | Independent Director | Other Derivative Acquisition | +42,180 | $17.52 |
| 2026-01-01 | Robert Duggan | Co-CEO & Executive Chairman | Other Derivative Acquisition | +11,232 | $17.52 |
| 2026-01-01 | Jeffrey Huber | Director | Other Derivative Acquisition | +44,885 | $17.52 |
| 2026-01-01 | Mostafa Ronaghi | Director | Other Derivative Acquisition | +35,000 | $17.52 |
| 2026-01-01 | Mahkam Zanganeh | Co-Chief Executive Officer | Other Derivative Acquisition | +11,232 | $17.52 |
| 2026-01-01 | Alessandra Cesano | Independent Non-Executive Director | Other Derivative Acquisition | +38,219 | $17.52 |
| 2026-01-01 | Yu Xia | -- | Other Derivative Acquisition | +35,000 | $17.52 |
| 2025-10-20 | Robert Duggan | Co-CEO & Executive Chairman | Private Acquisition | +13,980,789 | $18.74 |
| 2025-10-20 | Mahkam Zanganeh | Co-Chief Executive Officer | Private Acquisition | +293,488 | $18.74 |
| 2025-10-20 | Manmeet Soni | Chief Operating Officer | Private Acquisition | +53,361 | $18.74 |
| 2025-10-20 | Akeso, Inc. | -- | Private Acquisition | +533,617 | $18.74 |
| 2025-10-20 | Bhaskar Anand | Chief Accounting Officer & Head of Finance | Private Acquisition | +26,680 | $18.74 |
| 2025-09-17 | Bhaskar Anand | Chief Accounting Officer & Head of Finance | Other Derivative Acquisition | +50,000 | $19.23 |
| 2025-09-10 | Robert Duggan | Co-CEO & Executive Chairman | Open Market Acquisition | +338,394 | $17.68–18.07 |
| 2025-05-29 | Robert Duggan | Co-CEO & Executive Chairman | Derivative Exercise and Retained | +74,545 | $2.64 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:58:47 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
顶峰治疗 讨论区 0 条评论